Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.

Mass spectrometry better than routine for residual amyloidosis surveillance

12 Mar 2020

Mass spectrometry outperforms standard surveillance techniques in detecting residual disease in immunoglobulin light-chain (AL) amyloidosis, a recent study has found.

The study included 33 AL amyloidosis patients (median age, 56 years; 55 percent male) who had complete haematologic response and had negative bone marrow findings on six-colour flow cytometry. Serum (SIFE) and urine (UIFE) immunofixation electrophoresis, serum free light chain (FLC), and bone marrow measurements were performed as per standard practice.

Two additional surveillance techniques were used: matrix-assisted laser desorption/ionization-time-of-flight (TOF) mass spectrometry (MASS-FIX) and electrospray ionization and quadrupole TOF mass spectrometry (ESI-TOF).

Upon assessment of complete response, MASS-FIX and ESI-TOF found four participants with evidence of residual disease, resulting in a rate of 12 percent. These patients were previously thought to be in complete response as assessed by SIFE, UIFE, FLC and high-resolution bone marrow flow cytometry.

In turn, patients found positive in mass spectrometry techniques were significantly more likely to experience progression events by 50 months of follow-up than their negative comparators (75 percent vs 13 percent; p=0.003).

Moreover, 10-year survival estimates were also substantially lower in those who had residual disease, although the discrepancy failed to achieve statistical significance (62 percent vs 83 percent).

“Additional work in larger numbers of patients will ultimately be required to determine the range of sensitivity of mass spectroscopy of blood and urine has relative to the next-generation bone marrow testing, but these results are very promising,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.